Related Experiment Video
Updated: Apr 5, 2026
07:45
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
7.3K
Optimizing Endocrine Therapy for Breast Cancer
Amelia B Zelnak1, Ruth M O'Regan1
1From the Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University and Georgia Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, Georgia.
Journal of the National Comprehensive Cancer Network : JNCCN
|August 19, 2015
Summary
Endocrine therapy improves outcomes for hormone-receptor-positive breast cancer. This review addresses optimizing endocrine therapy, focusing on adjuvant duration, ovarian ablation, and incorporating targeted agents for advanced disease.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Endocrine therapy is a cornerstone in treating hormone-receptor (HR)-positive breast cancer, improving outcomes in both early and advanced stages.
- Despite its success, challenges persist, including relapse in early-stage disease and the development of resistance in advanced stages.
Purpose of the Study:
- To review and discuss the optimization of endocrine therapy for HR-positive breast cancer.
- To address controversial areas such as optimal adjuvant therapy duration, the role of ovarian ablation in premenopausal women, and the integration of targeted agents in metastatic settings.
Main Methods:
- Literature review and synthesis of current research on endocrine therapy resistance mechanisms.
- Analysis of clinical trial data and expert opinion on controversial aspects of endocrine therapy management.
Main Results:
- Recent advances in understanding endocrine resistance have led to new therapeutic approvals.
- Key unanswered questions include optimal adjuvant therapy duration, the utility of ovarian ablation, and combination strategies with targeted agents.
Conclusions:
- Optimizing endocrine therapy requires addressing patient-specific factors and evolving resistance mechanisms.
- Further research is needed to define best practices for adjuvant therapy duration and the integration of novel agents in metastatic HR-positive breast cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
02:49Cancer Therapies
10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
01:45Endocrine Signaling
69.5K
Endocrine cells produce hormones to communicate with remote target cells found in other organs. The hormone reaches these distant areas using the circulatory system. This exposes the whole organism to the hormone but only those cells expressing hormone receptors or target cells are affected. Thus, endocrine signaling induces slow responses from its target cells but these effects also last longer.
69.5K
01:27Tumor Immunotherapy
2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K